Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.

Collegium Pharmaceutical offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

Collegium provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. 

Collegium offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

 

Collegium's lead investors include Frazier Healthcare Partners, TPG Biotech, Boston Millennia Partners, Adage Capital Management among others. The company went public on May 7, 2015 and raised $80M at IPO with a valuation of $236.5M.

 

 

  • Year founded: 2002
  • Funding Info: $106M in 7 funding rounds (Last funding type: Venture - Series Unknown)/ Company went public on May 7, 2015 at an IPO Valuation of $236.5M
  • Yearly Revenue: $250M-$350M (2018)
  • Employee Size: 201-500
  • Business Valuation: Mkt Cap: $570.86M as of Jan 01, 2019
  • City/Town: Canton
  • State: Massachusetts
  • Country: United States
Related businesses